[go: up one dir, main page]

MX2020001835A - Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas. - Google Patents

Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.

Info

Publication number
MX2020001835A
MX2020001835A MX2020001835A MX2020001835A MX2020001835A MX 2020001835 A MX2020001835 A MX 2020001835A MX 2020001835 A MX2020001835 A MX 2020001835A MX 2020001835 A MX2020001835 A MX 2020001835A MX 2020001835 A MX2020001835 A MX 2020001835A
Authority
MX
Mexico
Prior art keywords
methods
ophthalmic diseases
patient
treatment
diabetic retinopathy
Prior art date
Application number
MX2020001835A
Other languages
English (en)
Other versions
MX386024B (es
Inventor
Ryo Kubota
Claes Olof Bavik
Susan Hayes Henry
Vladimir A Kuksa
Original Assignee
Acucela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acucela Inc filed Critical Acucela Inc
Publication of MX2020001835A publication Critical patent/MX2020001835A/es
Publication of MX386024B publication Critical patent/MX386024B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/20—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

En este documento se proporcionan métodos para el tratamiento de enfermedades o afecciones oftálmicas tales como enfermedades o trastornos oftálmicos asociados con la diabetes en un paciente. En este documento también se proporcionan métodos de tratamiento de la retinopatía del prematuro en un paciente. Adicionalmente, en este documento se proporcionan métodos para el tratamiento de la degeneración macular húmeda asociada a la edad en un paciente. Los métodos comprenden la administración de compuestos desvelados en este documento a un paciente que lo necesita, que inhiban o reduzcan uno o más signos o síntomas de dichas afecciones.
MX2020001835A 2012-05-04 2013-05-03 Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas. MX386024B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261643058P 2012-05-04 2012-05-04
US201261643178P 2012-05-04 2012-05-04
US201261643051P 2012-05-04 2012-05-04
US201361781907P 2013-03-14 2013-03-14
PCT/US2013/039562 WO2013166449A2 (en) 2012-05-04 2013-05-03 Methods for the treatment of diabetic retinopathy and other ophthalmic diseases

Publications (2)

Publication Number Publication Date
MX2020001835A true MX2020001835A (es) 2021-09-09
MX386024B MX386024B (es) 2025-03-18

Family

ID=49515046

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001835A MX386024B (es) 2012-05-04 2013-05-03 Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.
MX2014013341A MX2014013341A (es) 2012-05-04 2013-05-03 Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014013341A MX2014013341A (es) 2012-05-04 2013-05-03 Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.

Country Status (18)

Country Link
US (4) US9957224B2 (es)
EP (2) EP3741742A1 (es)
JP (6) JP2015518491A (es)
KR (1) KR20150013240A (es)
CN (3) CN116850163A (es)
AU (1) AU2013256029A1 (es)
BR (1) BR112014027571B1 (es)
CA (1) CA2872433C (es)
EA (1) EA201492031A1 (es)
ES (1) ES2792923T3 (es)
HK (2) HK1203478A1 (es)
IL (1) IL235446A0 (es)
MX (2) MX386024B (es)
PH (1) PH12014502449A1 (es)
SG (1) SG11201407162SA (es)
TW (1) TW201406707A (es)
WO (1) WO2013166449A2 (es)
ZA (1) ZA201408592B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009045479A1 (en) * 2007-10-05 2009-04-09 Acucela Inc. Alkoxy compounds for disease treatment
WO2011003103A2 (en) * 2009-07-02 2011-01-06 Acucela, Inc. Pharmacology of visual cycle modulators
HK1198514A1 (en) 2012-01-20 2015-05-15 Acucela, Inc. Substituted heterocyclic compounds for disease treatment
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
EA201591535A1 (ru) * 2013-03-12 2016-04-29 Акусела Инк. Замещенные производные 3-фенилпропиламина для лечения офтальмологических заболеваний и расстройств
EP2967999B1 (en) 2013-03-14 2017-04-19 Optimedica Corporation Laser capsulovitreotomy
US11447568B2 (en) 2014-04-10 2022-09-20 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
WO2017062990A1 (en) * 2015-10-09 2017-04-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
CA3054735A1 (en) * 2017-02-27 2018-08-30 Case Western Reserve University Visual cycle modulators
WO2019130583A1 (ja) * 2017-12-28 2019-07-04 株式会社ニコン 画像処理方法、画像処理プログラム、画像処理装置、画像表示装置、及び画像表示方法
MX2018008165A (es) * 2018-06-29 2019-12-30 Centro De Retina Medica Y Quirurgica S C Sistema portátil para la identificación de casos potenciales de edema macular diabético mediante procesamiento de imagen e inteligencia artificial.
EP3817808A4 (en) 2018-07-07 2022-04-06 Acucela Inc. DEVICE FOR PREVENTING RETINAL HYPOXIA
AU2019314262B2 (en) 2018-07-30 2025-04-03 Acucela Inc. An apparatus to treat myopia of an eye
CN112888440A (zh) * 2018-10-16 2021-06-01 豪夫迈·罗氏有限公司 Akt抑制剂在眼科中的用途
ES2970996T3 (es) * 2018-10-19 2024-06-03 Medicinova Inc Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast
WO2020240867A1 (ja) * 2019-05-31 2020-12-03 株式会社ニコン 画像処理方法、画像処理装置、及び画像処理プログラム
EP4003250A4 (en) 2019-07-31 2023-08-23 Acucela Inc. DEVICE FOR PROJECTING IMAGES ON THE RETINA
US11733545B2 (en) 2019-09-16 2023-08-22 Acucela Inc. Assembly process for an electronic soft contact lens designed to inhibit progression of myopia
US11777340B2 (en) 2020-02-21 2023-10-03 Acucela Inc. Charging case for electronic contact lens
CN111617313B (zh) * 2020-04-29 2022-09-06 天津医科大学眼科医院 一种眼用线性凝胶在作为临床孔源性视网膜脱离药物方面中的应用
US11320674B2 (en) 2020-05-13 2022-05-03 Acucela Inc. Electro-switchable spectacles for myopia treatment
JP2023529875A (ja) 2020-06-08 2023-07-12 アキュセラ インコーポレイテッド 非点収差を治療するための非対称投影を伴うレンズ
KR20230020391A (ko) 2020-06-08 2023-02-10 어큐셀라 인코포레이티드 누진 굴절 이상을 치료하기 위해 주변 디포커스를 이용하는 디바이스 상의 스틱
CA3174148A1 (en) 2020-06-08 2021-12-16 Acucela Inc. Projection of defocused images on the peripheral retina to treat refractive error
US11281022B2 (en) 2020-06-10 2022-03-22 Acucela Inc. Apparatus and methods for the treatment of refractive error using active stimulation
US11209672B1 (en) 2021-04-06 2021-12-28 Acucela Inc. Supporting pillars for encapsulating a flexible PCB within a soft hydrogel contact lens
US11366341B1 (en) 2021-05-04 2022-06-21 Acucela Inc. Electronic case for electronic spectacles
WO2022245697A1 (en) * 2021-05-16 2022-11-24 Metanoia Bio Inc. Methods and compositions for treating ocular neovascular disease
JPWO2022255332A1 (es) * 2021-06-03 2022-12-08
WO2024258981A2 (en) * 2023-06-12 2024-12-19 Synaptogenix, Inc. Methods for repairing nerve damage using pkc activating therapeutic agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
GEP20063755B (en) * 2001-11-09 2006-02-27 Eyetech Pharmaceuticals Use of VEGF Inhibiting Agents for Treating Ocular Neovascular Diseases
AU2005221283C1 (en) * 2004-03-17 2011-02-03 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
CN101686665B (zh) 2007-04-20 2014-04-23 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的苯乙烯基衍生化合物
CN101784188B (zh) * 2007-06-29 2014-02-12 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的炔基苯基衍生化合物
WO2009045479A1 (en) * 2007-10-05 2009-04-09 Acucela Inc. Alkoxy compounds for disease treatment
EP2111223A4 (en) 2007-11-01 2012-08-15 Acucela Inc AMINO-DERIVED COMPOUNDS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS
CN102203058B (zh) 2008-09-05 2014-11-12 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的连接有硫的化合物
JP5773877B2 (ja) * 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
WO2011003103A2 (en) 2009-07-02 2011-01-06 Acucela, Inc. Pharmacology of visual cycle modulators
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法

Also Published As

Publication number Publication date
TW201406707A (zh) 2014-02-16
BR112014027571B1 (pt) 2021-08-31
JP2023059991A (ja) 2023-04-27
BR112014027571A2 (pt) 2017-07-18
CN116850163A (zh) 2023-10-10
WO2013166449A2 (en) 2013-11-07
AU2013256029A1 (en) 2014-12-04
CN107865830A (zh) 2018-04-03
WO2013166449A3 (en) 2014-01-30
US10730825B2 (en) 2020-08-04
US20140039048A1 (en) 2014-02-06
US9957224B2 (en) 2018-05-01
ES2792923T3 (es) 2020-11-12
EA201492031A1 (ru) 2015-05-29
HK1246646A1 (zh) 2018-09-14
JP2020023535A (ja) 2020-02-13
EP2844636A2 (en) 2015-03-11
JP2018024702A (ja) 2018-02-15
JP2025069362A (ja) 2025-04-30
CA2872433C (en) 2022-06-28
EP2844636B1 (en) 2020-04-22
US20180346407A1 (en) 2018-12-06
JP2015518491A (ja) 2015-07-02
EP2844636A4 (en) 2016-03-09
PH12014502449A1 (en) 2015-01-12
US11795136B2 (en) 2023-10-24
JP2021075576A (ja) 2021-05-20
MX386024B (es) 2025-03-18
HK1203478A1 (en) 2015-10-30
CA2872433A1 (en) 2013-11-07
ZA201408592B (en) 2017-09-27
KR20150013240A (ko) 2015-02-04
SG11201407162SA (en) 2014-11-27
US20210171435A1 (en) 2021-06-10
MX2014013341A (es) 2015-06-02
EP3741742A1 (en) 2020-11-25
US20240308951A1 (en) 2024-09-19
IL235446A0 (en) 2014-12-31
CN104411678A (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
MX2020001835A (es) Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas.
MX2019008085A (es) Antagonistas de activina-actrii y usos para tratar transtornos oseos y otros.
GT201400162A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
GT201600007A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
GT201300215A (es) Inhibidores de glucosilceramida sintasa
UY33883A (es) Novedosos derivados heterocíclicos
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
BR112014032990A2 (pt) seringa
MX2014014166A (es) Metodos para mejorar la seguridad del transporte de la barrera hematoencefalica.
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
MX347226B (es) Tratamiento de enfermedad ocular.
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
CO2017005404A2 (es) Anticuerpos contra il-6
MX2016010328A (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
UY35055A (es) Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
UY33509A (es) Metodos y composiciones para el tratamiento de la alergia
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
GT201400179A (es) Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
CU20140096A7 (es) Fenilimidazopirazoles sustituidos y su uso
UY35054A (es) Combinaciones farmacéuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r